DISEASE SCANNER
Global Incurable Diseases Tracker
Pancreatic Cancer
A highly aggressive cancer with poor prognosis, often diagnosed at advanced stages. Majority are pancreatic ductal adenocarcinoma (PDAC). 5-year survival rate approximately 12%. Risk factors include smoking, chronic pancreatitis, diabetes, and family history.
495.0K
15
Symptoms
Treatment Options
Risk Factors
Diagnostic Methods
- 1Biopsy
- 2Imaging (CT, MRI, PET)
- 3Tumor markers
- 4Genetic testing
- 5Endoscopy
- 6Blood tests
- 7Screening programs
Prognosis
Resectable disease (15-20% of cases) has 20-25% 5-year survival with surgery + chemotherapy. Borderline resectable with neoadjuvant therapy has similar outcomes. Locally advanced unresectable has 12-18 months median survival with chemotherapy. Metastatic disease has 6-12 months median survival; FOLFIRINOX offers 11 months, gemcitabine/nab-paclitaxel offers 9 months. CA 19-9 is prognostic marker. Early diagnosis remains challenge; screening for high-risk groups being studied.
Prevention
- Smoking cessation
- Sun protection
- Healthy diet
- Regular exercise
- Vaccination (HPV, HBV)
- Screening programs
- Limit alcohol
- Maintain healthy weight
Research Status
Immunotherapy combinations (MSI-H tumors), PARP inhibitors for BRCA mutations. FOLFIRINOX and gemcitabine/nab-paclitaxel for advanced disease. CA 19-9 and emerging liquid biopsies for early detection.
Affected Countries
Sources
- https://www.cancer.gov
- https://www.who.int/cancer
- https://www.cancer.org
Medical Disclaimer
This information is for educational purposes only. Always consult healthcare professionals for medical advice, diagnosis, and treatment.